Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors [Immunotherapy]

Conclusion
AM0010 has an acceptable toxicity profile with early evidence of antitumor activity, particularly in RCC. These data support the further evaluation of AM0010 both alone and in combination with other immune therapies and chemotherapies.

Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Naing, Papadopoulos, Autio, Ott, Patel, Wong, Falchook, Pant, Whiteside, Rasco, Mumm, Chan, Bendell, Bauer, Colen, Hong, Van Vlasselaer, Tannir, Oft, Infante Tags: Clinical Trials, Phase I and Clinical Pharmacology Immunotherapy Source Type: research